IL10 and psoriatic arthritis: In a related study, McInnes et al. demonstrated that a 28-day course of subcutaneous administration of recombinant human IL-10 resulted in a clinically significant improvement of cutaneous lesions—but not joint symptoms—in 29 patients with psoriatic arthritis.